Novel Therapies for SMA Have Changed the Way Patients Are Classified, Dr Vamshi Rao Explained
The new therapies for spinal muscular atrophy (SMA) have had such a profound impact on disease trajectory that classification terminology has been changed, said Vamshi Rao, MD, attending physician, Children’s Hospital of Chicago, and assistant professor, Northwestern University Feinberg School of Medicine.
What We’re Reading: 340B Drugs Marked Up; Minnesota Nurses Strike; Cancer Drug Tops Chemotherapy
340B hospitals are marking up discounted drugs by 4.9 times the cost, per a Community Oncology Alliance report; thousands of nurses in Minnesota are striking due to understaffing and overworking; Amgen’s sotorasib performed better than a common chemotherapy for progression-free survival among patients.
Dr Igor Puzanov Discusses the State of Adjuvant Therapy for Advanced Melanoma
In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.
What We’re Reading: Biden Boosts Biotech; 9/11 Program Nearly Depleted; Tpoxx Safe in Monkeypox
President Joe Biden is set to sign an order to boost biotech as part of his Cancer Moonshot; the health care program for 9/11 survivors and first responders is running short on money; tecovirimat (Tpoxx) has been found to be safe in patients with monkeypox.
Dr Viral Shah Emphasizes Importance of Patient Education on T1D Technologies
The next step for health care professionals is to teach patients how to act on the data collected by intermittently scanned glucose sensing technologies, according to Viral Shah, MD, an endocrinologist and scientist.
FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement, a very rare and aggressive cancer.
What We’re Reading: Moderna Sues Pfizer; Access to Research; Monkeypox Cases Drop
Moderna is suing Pfizer-BioNTech for vaccine patent infringement; the White House is pushing for American citizens to have access to all publicly funded research by 2026; Monkeypox cases drop 21% globally, stopping a months-long increase.
Dr Sigrun Hallmeyer Highlights Clinical Achievements and Barriers in Melanoma
In this interview with The American Journal of Managed Care®, Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and co-director of medical research at Advocate Aurora Health, in Illinois, touches on several important topics within the melanoma space.
Five Additional States, Territories Join Medicaid’s Money Follows the Person Program
Medicaid’s Money Follows the Person (MFP) demonstration program, which began in 2008, has helped states transition more than 107,000 people to community settings rather than living in institutional facilities.
What We’re Reading: Premature Death Risk Factors; Pfizer Vaccine Efficacy; CVD Symptom Disparities
People who experienced childhood poverty and other adversities are at greater risk of premature death in adulthood; Pfizer’s COVID-19 vaccine is 73% effective in protecting children younger than 5 years; women experience more symptoms of heart failure and other cardiovascular diseases than men.